Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial

Leukemia

Volumn 11, Issue 1, 1997, Pages 37-41

  De Nully Brown, P ^a   Hoffmann, T ^a   Hansen, O P ^a   Boesen, A M ^b   Gronbaek K ^c   Hippe, E ^d   Jensen, M K ^e   Thorling, K ^b   Storm, H H ^f   Pedersen Bjergaard, J ^a  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Chemotherapy; Epidemiology; Secondary malignancies

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

EID: 8044231330     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400514     Document Type: Article

References (22)

1. Phillips CL, Reece DE, Shepherd JD, Barnett MJ, Brown RA, Frei-Lahr DA, Klingemann HG, Bolwell BJ, Spinelli JJ, Herzig RH. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77: 1429-1435.
2. Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood 1987; 69: 1551-1562.
3. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 1989; 7: 1260-1267.
4. Cassileth PA, Andersen JW, Bennett JM, Harrington DP, Hines JD, Lazarus HM, Mazza JJ, McGlave PP, O'Connell MJ, Paietta E, Wiernik P. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Co-operative Oncology Group. Leukemia 1992; 6 (Suppl. 2): 116-119.
5. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977-2982.
6. Champlin R, Gajewski J, Nimer S, Vollset S, Landaw E, Winston D, Schiller G, Ho W. Post-remission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol 1990; 8: 1199-1206.
7. Bandini G, Zuffa E, Rosti G, Battista R, D'Emilio E, Leoni F, Ciolli S, Barbui T, Bassan R, Todeschini G, Perona G, Scapoli GL, Mangoni L, Morra E, Di Prisco U, Visani G, Tura S. Long-term outcome of adults with acute myelogenous leukemia: results of a prospective, randomized study of chemotherapy with a minimal followup of 7 years. Br J Haematol 1991; 77: 486-490.
8. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, Killmann SA, Jensen MK, Karle H, Laursen B, Nielsen JB, Nissen NI, Thorling K. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial: the Danish Society of Hematology Study Group on AML, Denmark. Leukemia 1991; 5: 510-516.
9. Witherspoon RP, Fischer LD, Schoch G, Martin P, Sullivan KM, Sanders J, Deeg HJ, Doney K, Thomas D, Storb R, Donnall Thomas E. Secondary cancer after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med 1989; 321: 784-789.
10. Preisler HD, Anderson K, Rai K, Cuttner J, Yates J, DuPre E, Holland F. The frequency of long-term remission in patients with acute myelogenous leukemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol 1989; 71: 189-194.
11. Bennett JM, Andersen JW, Cassileth PA. Long-term survival in acute myeloid leukemia: the Eastern Co-operative Oncology Group (ECOG) experience. Leukemia Res 1991; 15: 223-227.
12. Buchner T, Hiddemann W, Wormann B, Loffler H, Maschmeyer G, Hossfeld D, Ludwig WD, Nowrousian M, Aul C, Schaefer UW, Sauerland C, Heinecke A. Long-term effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. Leukemia 1992; 6 (Suppl. 2): 68-71.
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Co-operative Group. Ann Intern Med 1985; 103: 620-625.
14. Storm HH, Manders T, Lecker S. Cancer Incidence in Denmark 1991. Danish Cancer Society: Copenhagen, 1994, pp 38-47.
15. Kaplan ES, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. SAS Institute Inc: SAS Technical Report P-179, additional SAS/STAT procedures, release 6.03. SAS Institute Inc: Cary, NC, 1988.
17. Buchner T, Hiddemann W, Schaefer UW, Loffler H, Maschmeyer G, Ludwig WD, Aul C, Lathan B, Heinecke A. Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML. Leukemia 1992; 6 (Suppl. 4): 68-70.
18. Zittoun RA, Mandelli F, Willemze R, de-Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotolli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Co-operative Groups. New Engl J Med 1995; 332:217-223.
19. Lowenberg B, Verdonck LJ, Dekker AW, Willemze R, Zwaan FE, de-Planque M, Abels J, Sonneveld P, van-der-Lelie J, Goudsmit R, van-Putten WLJ, Sizoo W, Hagenbeek A, de-Cast GC. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol 1990; 8: 287-294.
20. Pedersen-Bjergaard J, Philip P, Olesen Larsen S, Anderson M, Daugaard G, Ersboll J, Werner Hansen S, Hou-Jensen K, Nielsen D, Sigsgaard TC, Specht L, Østerlind K. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975-1986.
21. Kaldor J. Second cancer following chemotherapy and radiotherapy: an epidemiological perspective. Acta Oncol 1990; 29: 647-655.
22. Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL. Bone marrow transplantation versus high-dose cytarabin-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992; 10: 41-46.